NGL FINECHEM
Back to Balance Sheet
|
NGL FINECHEM Last 5 Year Total Non-Current Liabilities History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
Total Non-Current Liabilities | ₹6.32 Cr | ₹6.24 Cr | ₹8.06 Cr | ₹11 Cr | ₹12 Cr |
What is the latest Total Non-Current Liabilities ratio of NGL FINECHEM ?
Year | Total Non-Current Liabilities |
---|---|
Mar2024 | ₹6.32 Cr |
Mar2023 | ₹6.24 Cr |
Mar2022 | ₹8.06 Cr |
Mar2021 | ₹11 Cr |
Mar2020 | ₹12 Cr |
How is Total Non-Current Liabilities of NGL FINECHEM Trending?
Years | Total Non-Current Liabilities | % Change | |
---|---|---|---|
Mar2024 | ₹6.32 Cr | 1.27 | |
Mar2023 | ₹6.24 Cr | -22.60 | |
Mar2022 | ₹8.06 Cr | -27.82 | |
Mar2021 | ₹11 Cr | -3.92 | |
Mar2020 | ₹12 Cr | - |
Compare Total Non-Current Liabilities of peers of NGL FINECHEM
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
NGL FINECHEM | ₹1,135.3 Cr | 1.5% | -3.8% | -4% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹419,764.0 Cr | -1.6% | -6% | 46.1% | Stock Analytics | |
DIVIS LABORATORIES | ₹159,306.0 Cr | 0.4% | 3.9% | 64% | Stock Analytics | |
CIPLA | ₹120,459.0 Cr | 1.8% | 0.2% | 17.4% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹100,168.0 Cr | 0.5% | -7.9% | 6.7% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹95,662.7 Cr | 0.7% | -4% | 48.3% | Stock Analytics |
NGL FINECHEM Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
NGL FINECHEM | 1.5% |
-3.8% |
-4% |
SENSEX | 3.4% |
0.2% |
21.7% |
You may also like the below Video Courses